Posterior-Chamber Phakic Intraocular Lens Implantation in Patients over 40 Years of Age.
Journal
Journal of ophthalmology
ISSN: 2090-004X
Titre abrégé: J Ophthalmol
Pays: United States
ID NLM: 101524199
Informations de publication
Date de publication:
2020
2020
Historique:
received:
21
04
2020
accepted:
09
06
2020
entrez:
18
7
2020
pubmed:
18
7
2020
medline:
18
7
2020
Statut:
epublish
Résumé
To assess the efficacy, safety, and predictability of the Visian Implantable Collamer Lens (ICL) model having a central port in patients over 40 years of age. This study included 33 eyes from 21 patients who underwent V4c ICL implantation for the correction of myopia and myopic astigmatism. We assessed uncorrected (UDVA) and corrected (CDVA) distance visual acuity, refraction, intraocular pressure (IOP), endothelial cell density (ECD), vault, and adverse events occurring over a 1-year period. Mean age of the patients at the time of implantation was 43.52 ± 4.49 years (range: 40 to 56 years). Efficacy and safety indexes were 1 and 1.09, respectively. Surgical outcomes for CDVA were as follows: no eye lost any lines, 19 eyes (57.58%) showed no CDVA changes, 7 eyes (21.21%) gained 1 line, 4 eyes (12.12%) gained 2 lines, and 3 eyes (9.09%) gained ≥3 lines. Mean postoperative spherical equivalent (SE) was -0.09 ± 0.47 D. A total of 29 eyes (87.8%) were within ±0.50 D and 31 eyes (93.9%) were within ±1.00 D of the desired SE. At 1-year, mean IOP was 15.27 ± 3.03 mmHg (range: 9 to 20 mmHg, Our study's findings support the use of this lens in patients over 40 years of age. A long follow-up period is advisable to monitor ICL position relative to the crystalline lens.
Identifiants
pubmed: 32676203
doi: 10.1155/2020/7457902
pmc: PMC7341401
doi:
Types de publication
Journal Article
Langues
eng
Pagination
7457902Informations de copyright
Copyright © 2020 Pedro Tañá-Rivero et al.
Déclaration de conflit d'intérêts
Robert Montes-Micó declares research and consulting contracts with Alcon Laboratories, Essilor, Glaukos, and STAAR Surgical through the University of Valencia.
Références
J Cataract Refract Surg. 2015 Jun;41(6):1153-9
pubmed: 26189376
Sci Rep. 2017 Sep 12;7(1):11302
pubmed: 28900204
J Cataract Refract Surg. 2004 Nov;30(11):2269-76
pubmed: 15519074
Nepal J Ophthalmol. 2015 Jul;7(14):164-72
pubmed: 27363962
Ophthalmology. 2010 Aug;117(8):1506-11
pubmed: 20363503
Invest Ophthalmol Vis Sci. 1997 Mar;38(3):779-82
pubmed: 9071233
Vision Res. 2003 Oct;43(22):2363-75
pubmed: 12962993
J Ophthalmol. 2019 Oct 30;2019:9496326
pubmed: 31781381
J Cataract Refract Surg. 2019 Nov;45(11):1555-1561
pubmed: 31587936
Br J Ophthalmol. 2018 Apr;102(4):544-548
pubmed: 28729370
Br J Ophthalmol. 2018 Feb;102(2):177-181
pubmed: 28611132
J Cataract Refract Surg. 2012 Jan;38(1):46-53
pubmed: 22153092
Clin Ophthalmol. 2017 Jul 03;11:1253-1263
pubmed: 28740361
Ophthalmology. 2010 Jun;117(6):1245-50
pubmed: 20163862
J Cataract Refract Surg. 2004 Mar;30(3):576-83
pubmed: 15050252
Med Arch. 2017 Apr;71(2):93-96
pubmed: 28790537
J Refract Surg. 2019 Mar 1;35(3):169-176
pubmed: 30855094
Medicine (Baltimore). 2016 Apr;95(14):e3270
pubmed: 27057883
J Cataract Refract Surg. 2003 May;29(5):918-24
pubmed: 12781276
J Vis. 2008 Apr 28;8(4):29.1-20
pubmed: 18484868
J Refract Surg. 2011 Oct;27(10):765-76
pubmed: 21710954
Biomed Res Int. 2018 Jun 10;2018:6158520
pubmed: 29984242
JAMA Ophthalmol. 2016 May 1;134(5):487-494
pubmed: 26941076
Indian J Ophthalmol. 2019 Jul;67(7):1061-1065
pubmed: 31238411
BMC Ophthalmol. 2019 May 29;19(1):121
pubmed: 31142292
Clin Ophthalmol. 2018 Nov 27;12:2427-2438
pubmed: 30568421